WHO ICTRP trial
An exploratory clinical study on the efficacy and safety of tirelizumab combined…
ChiCTR2200063680 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2200063680 |
|---|---|
| Public title | An exploratory clinical study on the efficacy and safety of tirelizumab combined with gemcitabine and albumin paclitaxel in the treatment of borderline resectable pancreatic cancer |
| Primary sponsor | The Second Affiliated Hospital of the Army Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 1 |
| Countries | China |
| Conditions | Pancreatic cancer |
| Interventions | single arm:Treatment programs |
| Registration date | Sep 14, 2022 |
| Target size | single arm:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: